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Our search of current literature identified screening questions with high sensitivity for 
vWD. These questions were paired with proper initial testing for patients identified as 
“high risk” for vWD. A clinical pathway was designed to incorporate this information as 
well as to guide clinical decision making once test results were returned (Figure 1).
Von Willeband disease (vWD) is the most 
common inherited bleeding disorder, 
affecting about 1% of the population. 
Patients with vWD suffer from bruising, 
skin bleeding, epistaxis, prolonged 
mucosal bleeding, and prolonged 
bleeding after dental procedures. 
Though vWD has a prevalence of 1% in 
the population, only a fraction of these 
patients are diagnosed as having vWD. 
This gap in prevalence and diagnosis is 
caused in part by the reasonably mild 
nature of type 1 vWD, which accounts 
for the majority of cases; however, 
some patients remain undiagnosed 
secondary to failure of clinical recognition 
of the disease due to lack of bleeding 
challenges or failure to recognize minor 
excessive bleeding such as menorrhagia. 
The morbidity and mortality of patients 
with vWD is particularly concerning 
in young women and girls due to 
an increase in complications during 
menstruation, pregnancy, and potentially 
life threatening complications during 
delivery or the post-partum period. Due 
to the potential for significant morbidity 
and mortality in undiagnosed patients 
and the existence of readily available 
treatment Healthy People 2020 has 
called for an increase in the proportion 
of persons with hemoglobinopathies who 
are referred for evaluation and treatment, 
who receive early and continuous 
screening for complications, and who 
receive disease-modifying therapies. 
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Results Gathered
 
Development of a novel clinical pathway began with an extensive literature search 
to solidify information regarding vWD. This review provided information on when 
and what to test for, as well as, actionable steps to take regarding these test results. 
After the literature search was complete, a novel pathway was developed in order 
to facilitate a tool for guiding clinical decision. Pathway development was aimed at 
primary care providers and other healthcare providers of adolescent women and 
children. The pathway was completed and reviewed for accuracy and ease of use. 
Methodology
 The objective of this Capstone project 
is to raise awareness of vWD among 
healthcare providers of girls and young 
women and to develop a novel clinical 
pathway to guide physician decisions in 
screening and testing for vWD.
Problem Statement
 The objective of this Capstone project is to raise awareness of vWD among healthcare 
providers of girls and young women and to develop a novel clinical pathway to guide 
physician decisions in screening and testing for vWD.
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